262 related articles for article (PubMed ID: 29170074)
21. A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment.
Goss CH; Heltshe SL; West NE; Skalland M; Sanders DB; Jain R; Barto TL; Fogarty B; Marshall BC; VanDevanter DR; Flume PA;
Am J Respir Crit Care Med; 2021 Dec; 204(11):1295-1305. PubMed ID: 34469706
[No Abstract] [Full Text] [Related]
22. Exploring the Relationship between FEV
Hoff BM; Scheetz MH; Jain M; Cullina JF; Rhodes NJ
Pharmacotherapy; 2020 Jun; 40(6):584-591. PubMed ID: 32259317
[TBL] [Abstract][Full Text] [Related]
23. BEAT CF pulmonary exacerbations core protocol for evaluating the management of pulmonary exacerbations in people with cystic fibrosis.
Schultz A; McLeod C; Berry S; Marsh J; McKenzie A; Messer M; Wood J; Saville B; Jaffe A; Ranganathan S; Stick S; Wark P; Webb S; Snelling T
Trials; 2023 Mar; 24(1):211. PubMed ID: 36949472
[TBL] [Abstract][Full Text] [Related]
24. Antibiotics and outcomes of CF pulmonary exacerbations in children infected with MRSA and Pseudomonas aeruginosa.
Cogen JD; Hall M; Faino AV; Ambroggio L; Blaschke AJ; Brogan TV; Cotter JM; Gibson RL; Grijalva CG; Hersh AL; Lipsett SC; Shah SS; Shapiro DJ; Neuman MI; Gerber JS
J Cyst Fibros; 2023 Mar; 22(2):313-319. PubMed ID: 35945130
[TBL] [Abstract][Full Text] [Related]
25. Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis.
Bouzek DC; Ren CL; Thompson M; Slaven JE; Sanders DB
Pediatr Pulmonol; 2022 Jul; 57(7):1709-1716. PubMed ID: 35429154
[TBL] [Abstract][Full Text] [Related]
26. Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation.
Sanders DB; Khan U; Heltshe SL; Skalland M; West NE; VanDevanter DR; Goss CH; Flume PA;
J Cyst Fibros; 2022 Jul; 21(4):574-580. PubMed ID: 34857494
[TBL] [Abstract][Full Text] [Related]
27. Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations.
Waters V; Stanojevic S; Klingel M; Chiang J; Sonneveld N; Kukkar R; Tullis E; Ratjen F
J Cyst Fibros; 2015 Nov; 14(6):770-6. PubMed ID: 26265220
[TBL] [Abstract][Full Text] [Related]
28. Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations.
VanDevanter DR; O'Riordan MA; Blumer JL; Konstan MW
Respir Res; 2010 Oct; 11(1):137. PubMed ID: 20925941
[TBL] [Abstract][Full Text] [Related]
29. Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations.
Davis CS; Faino AV; Onchiri F; Gibson RL; Merjaneh L; Ramsey BW; Rosenfeld M; Cogen JD
Ann Am Thorac Soc; 2023 Jan; 20(1):75-82. PubMed ID: 36044723
[No Abstract] [Full Text] [Related]
30. SPLUNC1 as a biomarker of pulmonary exacerbations in children with cystic fibrosis.
Ben-Meir E; Perrem L; Shaw M; Ratjen F; Grasemann H
J Cyst Fibros; 2024 Mar; 23(2):288-292. PubMed ID: 38413298
[TBL] [Abstract][Full Text] [Related]
31. Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis.
VanDevanter DR; Heltshe SL; Spahr J; Beckett VV; Daines CL; Dasenbrook EC; Gibson RL; Raksha J; Sanders DB; Goss CH; Flume PA;
J Cyst Fibros; 2017 Sep; 16(5):607-615. PubMed ID: 28438499
[TBL] [Abstract][Full Text] [Related]
32. Oral antibiotic prescribing patterns for treatment of pulmonary exacerbations in two large pediatric CF centers.
Hoppe JE; Hinds DM; Colborg A; Wagner BD; Morgan WJ; Rosenfeld M; Zemanick ET; Sanders DB
Pediatr Pulmonol; 2020 Dec; 55(12):3400-3406. PubMed ID: 32970375
[TBL] [Abstract][Full Text] [Related]
33. Bronchodilator responsiveness in cystic fibrosis children treated for pulmonary exacerbations.
Pollak M; Shaw M; Wilson D; Solomon M; Ratjen F; Grasemann H
Pediatr Pulmonol; 2021 Jul; 56(7):2036-2042. PubMed ID: 33830642
[TBL] [Abstract][Full Text] [Related]
34. Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis.
Wagener JS; Williams MJ; Millar SJ; Morgan WJ; Pasta DJ; Konstan MW
J Cyst Fibros; 2018 Jul; 17(4):496-502. PubMed ID: 29685810
[TBL] [Abstract][Full Text] [Related]
35. Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes.
Sanders DB; Zhao Q; Li Z; Farrell PM
Pediatr Pulmonol; 2017 Oct; 52(10):1268-1275. PubMed ID: 28881091
[TBL] [Abstract][Full Text] [Related]
36. Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations.
Cogen JD; Faino AV; Onchiri F; Hoffman LR; Kronman MP; Nelson M; Nichols DP; Rosenfeld M; VanDevanter DR; Gibson RL
Ann Am Thorac Soc; 2020 Dec; 17(12):1590-1598. PubMed ID: 32726564
[No Abstract] [Full Text] [Related]
37. Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment.
Cogen JD; Faino AV; Onchiri F; Gibson RL; Hoffman LR; Kronman MP; Rosenfeld M; Nichols DP
Ann Am Thorac Soc; 2021 Feb; 18(2):266-272. PubMed ID: 32810412
[No Abstract] [Full Text] [Related]
38. Extending the course of intravenous antibiotics in adult patients with cystic fibrosis with acute pulmonary exacerbations.
Sequeiros IM; Jarad NA
Chron Respir Dis; 2012; 9(4):213-20. PubMed ID: 22637747
[TBL] [Abstract][Full Text] [Related]
39. IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis.
VanDevanter DR; Morris NJ; Konstan MW
J Cyst Fibros; 2016 May; 15(3):372-9. PubMed ID: 26603642
[TBL] [Abstract][Full Text] [Related]
40. A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care.
Sawicki GS; Ayyagari R; Zhang J; Signorovitch JE; Fan L; Swallow E; Latremouille-Viau D; Wu EQ; Shi L
Pediatr Pulmonol; 2013 Oct; 48(10):954-61. PubMed ID: 23255309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
